Table 1.

Demographic characteristics of study participants

	Pravastatin			Placebo
	N	Mean	S.D.	N	Mean	S.D.	t	p-Value
Age	30	42.57	11	30	44.53	12.55	0.65	0.47
Age of disease onset	29	21.1	7.37	30	22.03	6.74		0.62
Disease duration	29	20.89	13.13	30	22.5	12.77		0.64
Smoking duration	10	27.6	11.55	14	29.5	16.18		0.75

	Pravastatin			Placebo
		N	%	N	%	p-Value
Gender	Female	8	27	14	47	0.18
	Male	22	73	16	53
Race	Caucasian	19	63	20	67	0.67
	African American	4	13	5	17
	Asian	4	13	1	3
	Hispanic	1	3	3	10
	Native American	1	3	0	0
	Other	1	3	1	3
Hispanic Ethnicity	Hispanic	0	0	3	10	0.24
	Not Hispanic	30	100	27	90
Marital Status	Married	1	3	1	3	1
	Not married	29	97	29	97
Smoking status	Smokers	10	33	14	47	0.43
	Non smokers	20	67	16	53
Education	Middle school/some high school	4	14	6	20	0.83
	High School diploma	9	31	10	33
	Some college or higher	16	55	14	47
Diagnoses	Schizophrenia	17	57	16	53	1
	Schizoaffective	13	43	14	47
Medications	Typical Antipsychotics**	2	25	6	75	0.25
	Atypical antipsychotics	23	49	24	51	1
	Clozapine	11	58	8	42	0.58
	Olanzapine	5	50	5	50	1
	Aripiprazole	7	54	6	46	1
	Quetiapine	3	60	2	40	1
	Ziprasidone	1	20	4	80	0.35
	Paliperidone	3	75	1	25	0.61
	Risperidone	6	67	3	33	0.47
	Two Antipsychotics***	12	75	4	25	0.04

^*P-value obtained using Fisher’s exact test

^**Loxapine, Thiothixene, Perphenazine, Chlorpromazine

^***Any combination, typical and atypical antipsychotics